BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A, Scotto G, Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012;56:1254-8. [PMID: 22343167 DOI: 10.1016/j.jhep.2012.01.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Singh L, Bell TG, Yousif M, Kramvis A. Response of hepatitis B virus to antiretroviral treatment containing lamivudine in HBsAg-positive and HBsAg-negative HIV-positive South African adults. J Med Virol 2019;91:758-64. [PMID: 30515847 DOI: 10.1002/jmv.25375] [Reference Citation Analysis]
2 Caviglia GP, Olivero A, Ngatchou D, Saracco GM, Smedile A. Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. Minerva Gastroenterol Dietol 2019;65:77-8. [PMID: 30037184 DOI: 10.23736/S1121-421X.18.02517-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World J Gastroenterol 2012; 18(42): 6106-6113 [PMID: 23155339 DOI: 10.3748/wjg.v18.i42.6106] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
4 Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E. Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Curr Hepatology Rep 2014;13:256-63. [DOI: 10.1007/s11901-014-0236-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Giannini EG, Marenco S, Boni S, Beltrame A, Nicolini LA, Taramasso L, Feasi M, Grasso A, De Leo P, Percario G, Bartolacci V, Artioli S, Viscoli C, Cassola G, Testa R, Anselmo M, Riccio G, Savarino V, Picciotto A. Therapeutic Management of Chronic Hepatitis B in Clinical Practice: A Region-wide Survey. Journal of Clinical Gastroenterology 2015;49:228-34. [DOI: 10.1097/mcg.0000000000000106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
6 Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094 [PMID: 26673249 DOI: 10.3748/wjg.v21.i46.13087] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Coppola N, Alessio L, Gualdieri L, Pisaturo M, Sagnelli C, Minichini C, Di Caprio G, Starace M, Onorato L, Signoriello G, Macera M, Angelillo IF, Pasquale G, Sagnelli E. Hepatitis B virus infection in undocumented immigrants and refugees in Southern Italy: demographic, virological, and clinical features. Infect Dis Poverty. 2017;6:33. [PMID: 28179020 DOI: 10.1186/s40249-016-0228-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
8 Shouval D. Focus: Long-term treatment with lamivudine in HBeAg negative patients with chronic hepatitis B: to switch or not to switch? J Hepatol 2012;56:1219-20. [PMID: 22406736 DOI: 10.1016/j.jhep.2012.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Chevaliez S. Is HBsAg quantification ready, for prime time? Clin Res Hepatol Gastroenterol. 2013;37:559-563. [PMID: 23932705 DOI: 10.1016/j.clinre.2013.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
10 Wu Y, Jie Y, Li X, Huang M, Li X, Shi H, Chen S, Zhang M, Ao Y, Yang F, Gao Z, Lin G, Chong Y. Comprehensive analysis of hospital-based prospective cohort reveals the unique effectiveness and safety for nucleos(t)ide analogues in HBV patients. Clin Res Hepatol Gastroenterol 2016;40:213-20. [PMID: 26598028 DOI: 10.1016/j.clinre.2015.06.018] [Reference Citation Analysis]
11 Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302-311. [PMID: 23787007 DOI: 10.1016/j.jfma.2013.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
12 Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013;58:713-717. [PMID: 24183313 DOI: 10.1016/j.jcv.2013.09.020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
13 Boyd A, Gozlan J, Miailhes P, Lascoux-Combe C, Cam MS, Rougier H, Zoulim F, Girard PM, Lacombe K. Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus. AIDS 2015;29:1963-73. [PMID: 26153669 DOI: 10.1097/QAD.0000000000000795] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 4.8] [Reference Citation Analysis]
14 Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol. 2014;12:2106-2112.e1. [PMID: 24929235 DOI: 10.1016/j.cgh.2014.05.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
15 Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung M, Schott E, Fülöp B, Schlosser B, Berg T, van Bömmel F. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European Journal of Gastroenterology & Hepatology 2019;31:845-52. [DOI: 10.1097/meg.0000000000001351] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Yıldız Kaya S, Mete B, Kaya A, Balkan II, Saltoglu N, Tabak ÖF. The role of quantitative HBsAg in patients with HBV DNA between 2000-20,000 IU/ml. Wien Klin Wochenschr 2021;133:647-53. [PMID: 33914152 DOI: 10.1007/s00508-021-01854-7] [Reference Citation Analysis]
17 Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325-1332. [PMID: 24162593 DOI: 10.1136/gutjnl-2013-305517] [Cited by in Crossref: 186] [Cited by in F6Publishing: 175] [Article Influence: 20.7] [Reference Citation Analysis]
18 Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923-931. [PMID: 23468172 DOI: 10.1002/hep.26376] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
19 Su CW, Wu CY, Hung HH, Wu CH, Sheen IJ, Wu JC. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. J Gastroenterol Hepatol. 2013;28:1849-1858. [PMID: 23730852 DOI: 10.1111/jgh.12283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
20 Zhang J, Wen XY, Gao RP. Hepatitis B virus-related liver cirrhosis complicated with dermatomyositis: A case report. World J Clin Cases 2019; 7(10): 1206-1212 [PMID: 31183354 DOI: 10.12998/wjcc.v7.i10.1206] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Barone M, Iannone A, Leo AD. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy. World J Gastroenterol 2014; 20(26): 8722-8725 [PMID: 25024631 DOI: 10.3748/wjg.v20.i26.8722] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
22 Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis G, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno C. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. J Med Virol 2013;85:996-1004. [DOI: 10.1002/jmv.23567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
23 Jeng W, Sheen I, Chen Y, Hsu C, Chien R, Chu C, Liaw Y. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96. [DOI: 10.1002/hep.26549] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 16.7] [Reference Citation Analysis]
24 Kim JH, Choi YJ, Moon HW, Ko SY, Choe WH, Kwon SY. HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. Clin Mol Hepatol 2013;19:409-16. [PMID: 24459646 DOI: 10.3350/cmh.2013.19.4.409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]